Table 1 Baseline Patient Data.

From: Osteoprotegerin and Myocardial Fibrosis in Patients with Aortic Stenosis

Demographics

Mild/Moderate (N = 35)

Severe (N = 75)

p Value

Age, years

71 ± 10

78 ± 9

<0.001*

Male, n (%)

26 (74.3)

51 (68.0)

0.66

Hypertension, n (%)

13 (40.6)

44 (58.7)

0.096

SBP, mmHg

130 ± 19

130 ± 22

0.95

DBP, mmHg

71 ± 11

71 ± 13

0.46

Diabetes mellitus, n (%)

1 (3.8)

4 (6.1)

1.00

Current smoker, n (%)

2 (6.3)

3 (4.1)

0.64

Any coronary artery disease, n (%)

13 (37.1)

27 (36.0)

1.00

Previous stroke, n (%)

1 (2.9)

2 (2.7)

1.00

Atrial Fibrillation, n (%)

5 (14.3)

6 (8.0)

0.32

Hypercholesterolaemia, n (%)

18 (58.1)

50 (67.6)

0.38

NYHA Class ≥ II

19 (59.4)

60 (81.1)

0.03*

Caucasian

33 (94.3)

72 (96.0)

0.65

Height, cm

172 ± 12

168 ± 10

0.03*

Weight, kg

82 ± 18

75 ± 17

0.05

BMI, kg/m2

28 ± 5

26 ± 5

0.17

Pharmacotherapy

Aspirin, n (%)

19 (61.3)

44 (59.5)

1.00

Clopidogrel, n (%)

4 (13.8)

12 (16.7)

1.00

ACE-I/ARB, n (%)

13 (43.3)

38 (51.4)

0.52

Beta Blocker, n (%)

14 (46.7)

32 (44.4)

1.00

Calcium channel blocker, n (%)

8 (26.7)

6 (8.7)

0.03*

Diuretic, n (%)

14 (43.8)

43 (58.1)

0.21

Warfarin, n (%)

4 (14.3)

6 (8.3)

0.46

Amiodarone, n (%)

0 (0.0)

4 (5.6)

0.32

Statin, n (%)

20 (66.7)

54 (72.0)

0.64

Biochemical data

Osteoprotegerin, pmol/L

5.76 ± 1.96

7.91 ± 3.82

0.002*

Creatinine, μmol/L

93 ± 30

102 ± 36

0.20

NT-ProBNP (pg/mL)

1232 ± 1698

3813 ± 5489

0.002*

CRP (mg/L)

12 ± 22

15 ± 39

0.52

CMR data

CMR aortic valve area, cm2

1.2 ± 0.3

0.7 ± 0.1

<0.00001*

LVEF, %

62 ± 14

57 ± 17

0.11

LV Mass, g

166 ± 47

168 ± 57

0.87

No Myocardial Fibrosis, n (%)

13 (37.1)

23 (30.7)

0.82

Midwall Fibrosis, n (%)

11 (31.4)

27 (36.0)

0.82

Infarction Pattern Fibrosis, n (%)

11 (31.4)

25 (33.3)

0.82

LGE Mass

5.7 (7.6)

6.0 (7.9)

0.72

LGE Percent

3.4 (4.8)

3.8 (5.1)

0.71

Intervention

None

21 (60.0)

24 (32.0)

0.01*

AVR

9 (25.7)

25 (33.3)

0.01*

TAVR

5 (14.3)

26 (34.7)

0.01*

  1. Values are mean ± SD unless otherwise stated. *p < 0.05. Baseline data for AS patients based on severity. ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; AVR, aortic valve replacement; BMI, body mass index; CMR, cardiovascular magnetic resonance; DBP, diastolic blood pressure; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic blood pressure; TAVR, transcatheter aortic valve replacement.
Back to article page